TY - JOUR
T1 - Nonmelanoma huidkanker tijdens behandeling met TNF-blokkers bij psoriasis en reumatoïde artritis
AU - van Lümig, P. P. M.
AU - Menting, S. P.
AU - van den Reek, J. M. P. A.
AU - Spuls, P. I.
AU - van Riel, P. L. C. M.
AU - van de Kerkhof, P. C. M.
AU - Fransen, J.
AU - Kievit, W.
AU - de Jong, E. M. G. J.
PY - 2015
Y1 - 2015
N2 - To investigate if there was a difference in time to the occurrence of first non-melanoma skin cancer (NMSC) and in the incidence of NMSC between psoriasis patients and rheumatoid arthritis (RA) patients on TNF inhibitors. Prospective observational cohort study. We compared the time to first NMSC (expressed as hazard ratio) and the incidence of NMSC (expressed as incidence ratio) in psoriasis and RA patients in the Netherlands who were treated with TNF inhibitors and had a follow-up of at least one year. Cox regression and Poisson regression analyses were used; both were corrected for confounders (age, gender, disease duration, prior NMSC, duration of anti-TNF and other systemic therapies). The NMSC risk was significantly higher in the psoriasis group (fully adjusted hazard ratio: 6.0 [1.6 - 22.4 95% CI]) and time to first NMSC in psoriasis compared with RA was also shorter (1.6 years and 3.7 years, respectively). The incidence of NMSC was 5.5 times higher in psoriasis patients (2.2 - 13.4 95% CI) than in those with RA. The time to first NMSC was significantly shorter and the incidence of NMSC was significantly higher in psoriasis than in RA. This indicates that disease-related factors such as phototherapy may be important contributing factors to the occurrence of NMSC in psoriasis patients treated with TNF inhibitors
AB - To investigate if there was a difference in time to the occurrence of first non-melanoma skin cancer (NMSC) and in the incidence of NMSC between psoriasis patients and rheumatoid arthritis (RA) patients on TNF inhibitors. Prospective observational cohort study. We compared the time to first NMSC (expressed as hazard ratio) and the incidence of NMSC (expressed as incidence ratio) in psoriasis and RA patients in the Netherlands who were treated with TNF inhibitors and had a follow-up of at least one year. Cox regression and Poisson regression analyses were used; both were corrected for confounders (age, gender, disease duration, prior NMSC, duration of anti-TNF and other systemic therapies). The NMSC risk was significantly higher in the psoriasis group (fully adjusted hazard ratio: 6.0 [1.6 - 22.4 95% CI]) and time to first NMSC in psoriasis compared with RA was also shorter (1.6 years and 3.7 years, respectively). The incidence of NMSC was 5.5 times higher in psoriasis patients (2.2 - 13.4 95% CI) than in those with RA. The time to first NMSC was significantly shorter and the incidence of NMSC was significantly higher in psoriasis than in RA. This indicates that disease-related factors such as phototherapy may be important contributing factors to the occurrence of NMSC in psoriasis patients treated with TNF inhibitors
M3 - Article
C2 - 25970675
SN - 0028-2162
VL - 159
SP - A8865
JO - Nederlands Tijdschrift voor Geneeskunde
JF - Nederlands Tijdschrift voor Geneeskunde
ER -